Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

Stopped early · Phase 1

Conditions studied: Systemic Lupus Erythematosus

In brief

The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.

Key facts

Study ID

NCT00479622

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

20

Starts

2007-08-01

Expected to finish

2008-05-01

Last updated by the study team

2008-05-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit.
• Diagnosis of systemic lupus erythematosus more than 6 months before study day 1.
• History of positive antinuclear antibody titer of >1:160 or equivalent.
• Biopsy-proven class V lupus nephritis within the last 2 years.
• Have been on a stable dose of oral corticosteroids (<20 mg/day prednisone or equivalent) for 2 months before study day 1.

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Palo Alto, California, United States
• Study site — Lake Success, New York, United States
• Study site — Rochester, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.